4D Molecular Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| 4D Molecular Therapeutics, Inc. | FDMT - NASDAQ |
$22.00-$23.00 | $23.00 | $40.00 | 8.4 million | 12/11/2020 |
| Goldman Sachs, BofA Securities, Evercore | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): 1st Filed 2019-09-30 Filed 2020-11-17 Terms Added 2020-12-07 Terms Changed 2020-12-10 | ||||||
4D Molecular Therapeutics, Inc. Quote & Chart - Click for current quote - FDMT
IPO Boutique aggregates information on public companies and private companies, such as "FDMT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About 4D Molecular Therapeutics, Inc. (adapted from 4D Molecular Therapeutics, Inc. prospectus):
They are a clinical-stage gene therapy company pioneering the development of product candidates using our targeted and evolved AAV vectors.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage gene therapy company pioneering the development of product candidates using our targeted and evolved AAV vectors.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "FDMT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.